Cancer chemotherapy can be traced back to the 1940’s and since then the world has witnessed the discovery and the important application of several new drugs. The successes of combination chemotherapy suggested that all cancers can be treated provided that the correct combination of drugs at the correct doses and correct intervals are established. However, with time, tumor cells develop mechanisms of resistance to apoptosis and no longer respond to the majority of cytotoxic therapies. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy, edited by Benjamin Bonavida, reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. Such sensitizing agents target gene products that regulate resistance and therefore identify novel targets for drug development. This book also introduces several of the current approaches that have been developed by established investigators in the field that are aimed at overcoming resistance. This book is the first that compiles studies on tumor cell sensitization and is useful for students, scientists, clinicians and pharmaceutical companies.
Author(s): H. Peter Vollmers, Stephanie Brändlein (auth.), Benjamin Bonavida PhD (eds.)
Series: Cancer Drug Discovery and Development
Edition: 1
Publisher: Humana Press
Year: 2008
Language: English
Commentary: 38952
Pages: 420
Tags: Cancer Research; Oncology; Pharmacology/Toxicology; Immunology
Front Matter....Pages i-xxi
Sensitization of Epithelial Cancer Cells with Human Monoclonal Antibodies....Pages 3-11
Targeting the Transferrin Receptor to Overcome Resistance to Anti-Cancer Agents....Pages 13-27
Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways....Pages 29-39
Agents that Regulate DR5 and Sensitivity to TRAIL....Pages 41-49
Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer....Pages 51-60
Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease....Pages 63-80
Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy....Pages 81-114
Histone Deacetylase Inhibitors and Anticancer Activity....Pages 115-131
Eicosanoids and Resistance of Cancer Cells to Chemotherapeutic Agents....Pages 133-156
The RKIP and STAT3 Axis in Cancer Chemotherapy: Opposites Attract....Pages 159-174
Targeting Transcription Factors with Decoy Oligonucleotides: Modulation of the Expression of Genes Involved in Chemotherapy Resistance of Tumor Cells....Pages 175-187
p53 Inhibitors as Cancer Sensitizing Agents....Pages 189-202
Nitric Oxide—Induced Immunosensitization to Apoptosis by Fas-L and TRAIL....Pages 203-210
Natural Agents That Can Sensitize Tumor Cells to Chemotherapy and Radiation Therapy....Pages 211-240
Inhibitors of the Bcl-2 Protein Family as Sensitizers to Anticancer Agents....Pages 243-261
Therapeutic Targeting of Apoptosis in Cancer....Pages 263-278
Peptides and Peptidomimetics as Cancer Therapy Sensitizing Agents....Pages 279-303
Non-Peptidic Mimetics as Cancer-Sensitizing Agents....Pages 305-325
Sensitization of Cancer Cells to Cancer Therapies by Isoflavone and Its Synthetic Derivatives....Pages 327-335
Antisense Oligonucleotides and siRNA as Specific Inhibitors of Gene Expression: Mechanisms of Action and Therapeutic Potential....Pages 337-362
DNA Polymorphisms Affecting Chemosensitivity Toward Drugs....Pages 365-387
Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy....Pages 389-403
Back Matter....Pages 405-419
